Candriam S.C.A. Decreases Stock Position in Moderna, Inc. $MRNA

Candriam S.C.A. trimmed its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 21.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 220,986 shares of the company’s stock after selling 60,960 shares during the period. Candriam S.C.A. owned approximately 0.06% of Moderna worth $6,097,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. S Bank Fund Management Ltd bought a new position in shares of Moderna during the first quarter valued at $25,000. TD Private Client Wealth LLC raised its position in Moderna by 348.8% in the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after buying an additional 743 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new position in Moderna in the 2nd quarter worth about $26,000. SVB Wealth LLC bought a new position in Moderna during the 1st quarter valued at about $28,000. Finally, Whittier Trust Co. purchased a new stake in shares of Moderna during the 2nd quarter valued at about $28,000. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of MRNA stock opened at $24.77 on Friday. Moderna, Inc. has a 1 year low of $23.04 and a 1 year high of $48.92. The firm has a fifty day moving average price of $25.92 and a 200-day moving average price of $27.08. The company has a market cap of $9.68 billion, a price-to-earnings ratio of -3.07 and a beta of 2.02.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($2.15) by $1.64. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $893.29 million. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.Moderna’s revenue for the quarter was down 45.4% compared to the same quarter last year. During the same period last year, the firm earned $0.03 EPS. Moderna has set its FY 2025 guidance at EPS. Equities research analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MRNA. Weiss Ratings reissued a “sell (e+)” rating on shares of Moderna in a report on Wednesday, October 8th. Barclays cut their target price on shares of Moderna from $31.00 to $25.00 and set an “equal weight” rating for the company in a research report on Friday, November 7th. UBS Group lowered their price target on Moderna from $70.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, October 23rd. Evercore ISI set a $32.00 price target on Moderna in a research note on Friday, August 1st. Finally, Morgan Stanley upped their price objective on Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a research report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have given a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average target price of $35.85.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.